Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Te… (NCT02408354) | Clinical Trial Compass
CompletedPhase 2
Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood
France10 participantsStarted 2015-03-25
Plain-language summary
The purpose of this project is to study the efficacy of triheptanoin oil in patients with Alternating Hemiplegia of Childhood (AHC) due to ATP1A3 gene mutation.
Who can participate
Age range15 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* AHC with mutation in ATP1A3 gene
* Age ≥ 15 years and 3 months
* ≥ 6 neurological paroxystic events during the last 3 months prior to the beginning of the study
* No specific diet
* Covered by french social security
* Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent. (In addition to the requirement for the consent of parents or the legal representative, adolescents can provide additional informed consent to participate in clinical trials)
Exclusion Criteria:
* Age \< 15 years and 3 months
* Evidence of psychiatric disorder
* Comorbid medical condition that would render them unsuitable for the study, e.g. HIV, diabetes
* Pregnant or parturient or lactating women
* Absence of double effective contraception at the women old enough to procreate
* Unwillingness to be informed in case of abnormal MRI
* Absence of signed informed consent
* No covered by french social security
* Persons deprived of their liberty by judicial or administrative decision
* Person subject to an exclusion period for another research
* Subjects with exclusion criteria required by french law
What they're measuring
1
Number of neurologic paroxystic events report in patient diary
Timeframe: 7 months
Trial details
NCT IDNCT02408354
SponsorInstitut National de la Santé Et de la Recherche Médicale, France